目的 探讨振源胶囊联合沙格列汀治疗2型糖尿病的临床效果。方法 选取2017年2月-2018年2月在皖南医学院弋矶山医院就诊的2型糖尿病患者155例，随机分成对照组（77例）和治疗组（78例）。对照组患者口服沙格列汀片，1片/次，1次/d；治疗组患者在对照组基础上口服振源胶囊，2粒/次，3次/d。两组患者均连续治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者血清指标水平、稳态模型评价（HOMA）和不良反应情况。结果 治疗后，对照组临床有效率为85.71%，显著低于治疗组的96.15%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者空腹血糖和糖化血红蛋白（HbA1c）水平均显著降低（P<0.05），空腹C肽水平显著升高（P<0.05），且治疗组这些指标水平明显优于对照组（P<0.05）。治疗后，两组患者HOMA-IS和HOMA-β水平显著升高（P<0.05），HOMA-IR水平显著降低（P<0.05），且治疗组患者HOMA指标水平明显优于对照组（P<0.05）。治疗期间，治疗组患者药物不良反应发生率为3.85%，显著低于对照组的14.29%，两组比较差异具有统计学意义（P<0.05）。结论 振源胶囊联合沙格列汀治疗2型糖尿病降糖效果显著，不良反应低，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Zhenyuan Capsules combined with saxagliptin in treatment of type 2 diabetes. Methods Patients (155 cases) with type 2 diabetes in Yijishan Hospital of Wangnan Medical College from February 2017 to February 2018 were randomly divided into control (77 cases) and treatment (78 cases) groups. Patients in the control group were po administered with Saxagliptin Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Zhenyuan Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the serum index levels, HOMA, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.71%, which was significantly lower than 96.15% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the fasting blood-glucose and HbA1c in two groups were significantly decreased (P<0.05), but the fasting C-peptide levels were significantly increased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the HOMA-IS and HOMA-β levels in two groups were significantly increased (P<0.05), but HOMA-IR levels were significantly decreased (P<0.05), and the HOMA indexes levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 3.85%, which was significantly lower than 14.29% in the control group, with significant difference between two groups (P<0.05). Conclusion Zhenyuan Capsules combined with saxagliptin has significantly hypoglycemic effect on type 2 diabetes with low incidence of adverse reactions, which has a certain clinical application value.